

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
APPLICATION AND FEE TRANSMITTAL

031088 U.S.PTO
10/680684



Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is a request for filing a continuation patent application divisional patent application under 37 C.F.R. §1.53(b), of pending prior application Serial No. 09/904,621 filed on July 13, 2001 entitled NOVEL HUMAN KUNITZ-TYPE INHIBITORS AND METHODS RELATING THERETO, incorporated herein by reference.

Prior Examiner: Prema Maria Mertz

Prior Art Unit: 1646

Enclosed are the following papers:

50 pages of specification
 2 sheets of Declaration and Power of Attorney
 _____ sheets of Figures
 6 pages of sequence listing

A Preliminary Amendment is enclosed.

The prior application is assigned of record to ZymoGenetics, Inc. recorded on May 31, 1995, Reel 7665, Frame 0568 and The University of New Mexico recorded on May 28, 1996, Reel 7967, Frame 0160.

Address all future communications to Brian J. Walsh, Patent Department, ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, Washington 98102.

Enclosed is a ASCII Computer Disk Sequence pursuant to 37 C.F.R. 1.821(f). It is believed that the content of the paper sequence listing and the computer readable sequence listing are the same.

CALCULATION OF APPLICATION FEE

Claim Type	No. Filed	Less	Extra	Extra Rate	Fee
Total	6	-20	0	\$9.00	\$000.00
Independent	1	-3	0	\$43.00	\$000.00
					\$385.00
					\$000.00
					\$000.00
					\$385.00

Basic Fee
Multiple Dependency Fee
If Applicable (\$145.00)
Total Filing Fee

Applicants claim small entity status. Please charge ZymoGenetics, Inc., Deposit Account No. 26-0290 as follows:

- Filing fee, estimated to be \$385
- Assignment recording fee
- Any additional fees associated with this paper or during the pendency of this application.
- The issue fee set in 37 C.F.R. 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

A copy of these sheets is enclosed.

Respectfully submitted,



Brian J. Walsh
Registration No. 45,543

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: U.S. Patent Application for
NOVEL HUMAN KUNITZ-TYPE INHIBITORS AND METHODS RELATING
THERETO

Applicants: Cindy A. Sprecher, Walt Kisiel, Donald C. Foster

Sir:

Express Mail Label No. EV 331816199US

Date of Deposit October 7, 2003


I hereby certify that the following attached paper(s) or fee

1. Return Post card
2. Application And Fee Transmittal (in duplicate)
3. Patent Application (50 pages)
4. Copy of Executed Declaration and Power of Attorney
5. Sequence Listing (6 pages)
6. Letter Regarding Sequence Listing
7. Letter Identifying Changes

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee"
under 37 C.F.R. 1.10 on the date indicated above, addressed to the Commissioner for Patents, P.O.
Box 1450, Alexandria, VA 22313-1450.


Kim M. Goplen

ZymoGenetics, Inc.
1201 Eastlake Avenue East
Seattle, WA 98102
(206) 442-6600



Express Mail Label No. EV 331816199US

PATENT APPLICATION
File No.: 93-14D4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Cindy A. Sprecher, Walt Kisiel, Donald C. Foster
For: NOVEL HUMAN KUNITZ-TYPE INHIBITORS AND
METHODS RELATING THERETO
Filed: October 7, 2003

LETTER IDENTIFYING CHANGES

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The specification submitted herewith has been amended from the parent application as follows:

Page 1 has been amended to include a Cross-Reference to Related Applications.

The instant continuing patent application includes a new set of claims. The claims are directed only to subject matter disclosed in the prior application.

No new matter has been added.

Respectfully submitted,



Brian J. Walsh
Registration No. 45,543